Monocinque retard caps. Prolong 50 mg 30 pcs

Description

Composition
Active substance:
1 capsule contains: 50 mg of isosorbide-5-mononitrate.
Excipients:
Sucrose, corn starch, ethylcellulose, stearic-ta, talc, red dye 4 R (E 124), quinoline yellow (E 104), titanium dioxide, gelatin.
Description:
Hard gelatin capsules pinkish-orange, containing white granules, type “2” average size.
Product form:
Capsules retard 50 mg.
One cardboard box contains two blisters (each 15 capsules) together with instructions for use (№ 30).
Contraindications
Hypersensitivity to isosorbide (mono- dinitrate, and other organic nitrates), acute circulatory disorders (shock, circulatory collapse), hemorrhagic stroke, acute phase of myocardial infarction, simultaneous phosphodiesterase inhibitors sildenafil (Viagra®, Viagra), because sildenafil potentiates the hypotensive effect of nitrates, marked hypotension (systolic blood pressure less than 90 mm Hg. v., diastolic blood pressure below 60 mm Hg. v.), post-traumatic brain injury, Children under 18 years of closure glaucoma deficiency of glucose-6-phosphate dehydrogenase.
Dosage
50 mg
Indications
Prevention and long-term treatment of angina III – IV functional class,
Reducing treatment after myocardial infarction,
Treatment of chronic heart failure (in a combination therapy).
Interaction with other drugs
While admission Monochinkve® retard with other vasodilators, antihypertensives, beta blockers, calcium channel blockers, antipsychotics, tricyclic antidepressants, sildenafil, ethanol may potentiate the hypotensive effect Monocinque administered retard.
Overdose
No cases of overdose have been reported. However, when conventional measures are recommended if symptoms occur overdose cause vomiting and stomach wash. It is necessary to monitor whether the patient is taking at the same time has any medication, follow the hypodynamic indicators.
pharmachologic effect
Pharmacological group:
Antianginal agent nitrate.
Pharmacological properties:
Active substance formulation Monocinque administered retard – isosorbide – 5 – mononitrate exerts vasodilating and antianginal effect. At the molecular level, it acts through the formation of nitric oxide (NO) and cyclic guanosine monophosphate (cGMP), reduction in calcium concentration in smooth muscle cells. Decreases preload (due to expansion of peripheral veins) and afterload (due to a decrease in total peripheral soudistogo resistance) reduces myocardial oxygen demand, expanding coronary artery and improves coronary blood flow, facilitates its redistribution in the ischemic area, reduces the end-diastolic volume of the left ventricle and decreases systolic voltage of its walls. Improves exercise capacity in patients with ischemic heart disease, reduces the pressure in the pulmonary circulation.
Special Monocinque administered retard formulation with sustained release of the active substances ensures that after a single daily dose, concentration in blood provides a therapeutic effect for at least 24 hours. The medicament is particularly suitable for long-term treatment of coronary heart disease.
Pharmacokinetics:
The drug is rapidly and completely absorbed in the gut after oral administration. Oral bioavailability is from 90 to 100%. It has no effect of “first pass through the liver.” The level of plasma concentration of the drug at approximately the same oral and parenteral route of administration. The maximum concentration is achieved in the blood plasma after 1 – 1.5 h after dosing. The half-life of about 5 hours, about 8 times higher than that of isosorbide dinitrate. Isosorbide 5- mononitrate exclusively eliminated via the kidneys as metabolites. Approximately 2% is excreted unchanged.
Pregnancy and breast-feeding
During pregnancy, the drug can be appointed only if absolutely necessary, when benefit to the mother outweighs the potential risk to the fetus. If there is a need to take the drug during lactation, the breast-feeding should be discontinued.
Conditions of supply of pharmacies
Available on prescription !.
side effects
The recommended dosage authentic side effects are not described. However, as the reception of other nitrates possible “nitrate” headache at the beginning of treatment. With continued therapy, it usually decreases after a few days.
After the first dose, or after increasing doses of the drug may occur lowering blood pressure and / or the development of orthostatic hypotension, that may be accompanied by tachycardia, dizziness, and general weakness.
Very rarely can be observed nausea, vomiting, facial flushing and skin allergic reactions.
special instructions
In the case of hypertension drug should be taken under medical supervision only.
The drug is not used for the relief of angina attacks.
The drug is used alone or in combination with beta adrenoblokatorami, calcium channel blockers, ACE inhibitors, cardiac glycosides, or diuretics.
While taking the drug may reduce the ability to react quickly, and therefore, is not recommended to drive vehicles and occupation of other potentially hazardous activities.
Storage conditions
Store in a dark place at a temperature not higher than 25 C.
Keep out of the reach of children.
Dosing and Administration
In the absence of other requirements prescribed 1 capsule retard Monocinque administered 1 time per day in the morning after a meal with liquid squeezed small amount of liquid.
Korregirovat dose may physician according to the patient’s condition.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist